Electronic search in general practices to identify individuals at risk of developing T2D by using the Cambridge Risk Score or by a record of non-diabetic hyperglycaemia using HbA1c, impaired glucose tolerance or impaired fasting glucose.
Approach previous study volunteers who have provided consent to be re-approached for future studies and who appear eligible for the current trial.

**Invitation letter and information sheet to be posted or given at community centre to potential participants. Enclose a return slip. Contact participant after 7 days by telephone and invite them to a recruitment appointment at a practice or research facility.**

**Pre-trial**

**1st visit - Day1**

Obtain informed consent and answer any queries. Take ionised calcium, serum calcium, urine calcium:creatinine ratio and random blood glucose safety sample. Ensure negative pregnancy result in women of childbearing age.

Do anthropometric measurements (including pulse wave velocity (PWV) in London only) and other blood samples. Give participant 1st dose of investigational medicinal product (IMP)/placebo and information sheet with contact details. Set a date for next appointment.

**2nd visit - 1 month**

Take safety samples (serum calcium – POC (point of care) test and urine Ca:Cr ratio). Give participant 2nd dose of IMP/placebo. Set a date for next appointment.

**3rd visit – 2nd month**

Take safety samples (serum calcium – POC test and urine Ca:Cr ratio). Give participant 3rd dose of IMP/placebo. Give participant 4th dose of IMP/placebo to take on 90th day. Set a date for next appointment.

**3rd month**

Telephone call reminder to take 4th dose of IMP/placebo

**4th visit – 4th month**

Take blood samples. Do anthropometric measurements (and PWV in London only). Complete questionnaires.